Recombinant analogues of IFNα2 and IFNβ1, and more recently pegylated forms of IFNα2, have found wide application for the treatment of chronic viral hepatitis and remitting relapsing multiple sclerosis (RRMS) respectively. The gene discussed is IFNA2; the disease is relapsing-remitting multiple sclerosis.